Millipore Corporation has entered into a worldwide, non-exclusive license agreement with Bayer HealthCare AG, a subsidiary of Bayer AG, to use Millipore's Ubiquitous Chromatin Opening Element technology to manufacture its biologic drugs
Millipore Corporation has entered into a worldwide, non-exclusive license agreement with Bayer HealthCare AG, a subsidiary of Bayer AG, to use Millipore's UCOE(TM) (Ubiquitous Chromatin Opening Element) technology to manufacture its biologic drugs. Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. The license will enable Bayer to more efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations. Financial terms were not disclosed.
Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. It plans to expand the use of the UCOE technology from small-scale use in research and development to large scale manufacturing in order to help it reduce the high cost of manufacturing recombinant protein-based drugs.
The process of manufacturing biologic drugs such as recombinant proteins often begins with growing mammalian cells in a bioreactor. These cells act as "factories" and produce the proteins that form the basis of biologic drugs. Millipore's UCOE technology helps biopharmaceutical companies to effectively identify which cells will be the most effective in producing proteins during large-scale manufacturing.